June 10, 2024 Regulatory Bulletin from the Extraordinary General Meetings in InDex Pharmaceuticals Holding AB (publ) on June 10, 2024 Read more
June 7, 2024 Regulatory InDex Pharmaceuticals has received a conditional approval for continued listing on Nasdaq First North Growth Market after the reverse merger of Flerie Read more
May 27, 2024 Regulatory InDex Pharmaceuticals publishes company description in connection with the reverse merger of Flerie Read more
May 23, 2024 Regulatory Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 20, 2024 Regulatory InDex Pharmaceuticals has entered into a conditional agreement regarding a reverse merger with Flerie Read more
May 7, 2024 Regulatory Bulletin from the Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2024 Regulatory Notice of extraordinary general meeting in InDex Pharmaceuticals Holding AB (publ) Read more
May 6, 2024 Non Regulatory InDex Pharmaceuticals provides a status update and informs about Extraordinary General Meeting on June 10, 2024 Read more
April 26, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) interim report January – March 2024 Read more
April 22, 2024 Regulatory InDex Pharmaceuticals brings forward the publication of the interim report for Q1 2024 Read more
April 8, 2024 Regulatory InDex Pharmaceuticals Holding AB (publ) publishes Annual Report for 2023 Read more
April 5, 2024 Regulatory Notice of Annual General Meeting in InDex Pharmaceuticals Holding AB (publ) Read more
February 26, 2024 Non Regulatory InDex Pharmaceuticals provides an update on company’s future Read more
February 26, 2024 Regulatory InDex Pharmaceuticals discontinues the development of cobitolimod Read more
January 19, 2024 Regulatory InDex Pharmaceuticals announces expected cash balance per March 31, 2024 Read more